| Name | Pixantrone dimaleate |
| Description | Pixantrone dimaleate (Pixantrone Maleate) (BBR 2778 dimaleate) is an experimental antineoplastic drug. |
| Kinase Assay | Recombinant RT enzymes are expressed, purified, and assessed for inhibition by Efavirenz (L-743726). Ki and Kii values are determined for each enzyme tested. The wild-type RT exhibited exclusively noncompetitive inhibition kinetics (data not shown), and, therefore, the Ki and Kii values are identical. Pure noncompetitive inhibition is not assumed for the mutant enzymes, and, hence, the values of both Ki and Kii are obtained from the linear mixed-type inhibition equation. The two- to threefold differences between the Ki and Kii values probably reflect a small contribution of competitive inhibition with the mutant RTs[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 91 mg/mL (163.31 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 1 mg/mL (1.79 mM), Sonication is recommended.
|
| Keywords | Topoisomerase | Pixantrone Maleate | Pixantrone | MDCK cell | K562 cell | intercalator | BBR-2778 Dimaleate | BBR2778 Dimaleate | BBR2778 | BBR 2778 |
| Inhibitors Related | Ciprofloxacin hydrochloride monohydrate | Berberine chloride | EIDD-1931 | Levofloxacin hydrochloride | Norfloxacin | Anthraquinone | Prulifloxacin | 1,4-Naphthoquinone | Ofloxacin | Levofloxacin | 3-Hydroxypyridine | Etoposide |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |